The results for the 2nd quarter of 2019 were released on July 30.
CARE and LIVE
Our Annual Report, Corporate Magazine and Company Profile 2018 are now available.
Find out how we unite our vision as a caregiver (CARE) with the wishes of our dialysis patients (LIVE).
Underlying business development in line with expectations; Continued strong organic revenue growth; Healthy growth in the U.S. dialysis business
Fresenius Medical Care is pleased the U.S. Administration’s plans for changing the way care is provided to people with kidney disease supports its existing strategy.
Fresenius Medical Care North America (FMCNA) has announced an investment in BioIntelliSense, a Denver-based company that is developing a medical grade data services platform for continuous remote...
Read more about our main financing instruments, senior notes and the credit ratings.